Applied DNA Sciences에 대한 매도 수량은 투자자에게 Applied DNA Sciences의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Applied DNA Sciences (NASDAQ:APDN) 주식, 공매도 수량 보고

Applied DNA Sciences

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

micron-ext-building

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APDN

수요일(18일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다. 제너럴 밀스, 워딩턴 엔터프라이즈, 자빌, 어플라이드 DNA 및 마이크론

수요일 주목해야 할 주식: 제너럴 밀스, 워딩턴 엔터프라이즈, 자빌, 어플라이드 DNA 및 마이크론

wall-street-ai17

Broad U.S. Equity ETFs

Exclusives

Tech

ETFs

AAPL

AMZN

ASTS

CING

CRWD

GOVX

INDO

LUMN

LUNR

NVDA

PLTR

SERV

SMCI

TSLA

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences Inc

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALMS

BFRG

IMAB

IRWD

MTSR

RSLS

STSS

THRD

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

General

Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares are trading higher by 6.0% to $1.76 during Tuesday&#8217;s session after the company announced it positioned its TR8 PGx testing as <a href="https://www.benzinga.com/pressreleases/25/04/ac44586006/applied-dna-positions-tr8-pgx-testing-service-as-pre-emptive-testing-for-safety-of-fluoropyrimidi">pre-emptive testing</a> for therapeutic safety.
What To Know: Applied DNA Sciences on Tuesday announced that its subsidiary, Applied DNA Clinical Labs (ADCL), is refining its TR8 PGx pharmacogenomics testing service by offering specialized subpanels for specific medical conditions. 
The first subpanel targets patients with DPYD gene variants, which can affect metabolism of chemotherapy drugs fluorouracil (5-FU) and capecitabine (Xeloda), potentially leading to severe toxicities. This move follows an FDA safety notice emphasizing the risks for patients with DPD enzyme deficiencies. 
ADCL's TR8 PGx test, approved in New York, screens for over 33 drug metabolism genes. CEO Dr. James A. Hayward highlighted plans for additional subpanels in oncology, cardiology and psychiatry to enhance clinical decision-making and increase adoption of PGx testing.
Read Also: <a href="https://www.benzinga.com/25/04/44586120/whats-going-on-with-rigetti-computing-stock-today">What&#8217;s Going On With Rigetti Computing Stock Today?</a>
<h2 class="wp-block-heading">How To Buy APDN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Applied DNA Sciences&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APDN has a 52-week high of $460.00 and a 52-week low of $1.45.

Why Applied DNA Sciences (APDN) Stock Is Rising

WIIM

Applied DNA Sciences shares are trading higher after the company announced it positioned its TR8 PGx testing as pre-emptive testing for therapeutic safety.

- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases -

Biotech

Applied DNA Sciences Positions TR8 PGx Testing Service As Pre-Emptive Testing For Safety Of Fluoropyrimidine-Based Cancer Therapeutics Following Publication Of FDA Safety Announcement

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 22.7% to $2.7 during Wednesday's after-market session. The market value of their outstanding shares is at $31.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 15.41% to $0.1. The company's market cap stands at $13.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares increased by 11.09% to $2.81. The market value of their outstanding shares is at $87.5 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 10.41% to $0.53. The market value of their outstanding shares is at $16.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares rose 7.94% to $1.9. The company's market cap stands at $135.3 million. The company's, Q4 earnings came out today. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares rose 7.19% to $7.6. The market value of their outstanding shares is at $660.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 20.8% to $0.11 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock fell 12.14% to $3.33. The market value of their outstanding shares is at $64.1 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) stock fell 9.1% to $10.5. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out today. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 8.71% to $0.64. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 8.0% to $1.9. The company's market cap stands at $2.0 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 5.84% to $1.28. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

AEON

ALVO

IMNM

OCEA

OSRH

PRPH

PTPI

SILO

ZNTL

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

BCLI

DYAI

FGEN

IPSC

LENZ

SCNX

SHPH

VERO

YCBD

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Applied DNA Sciences shares are trading lower after the company announced a 1-for-50 reverse stock split.

Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.28) by 100 percent. This is a 522.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $1.20 million which beat the analyst consensus estimate of $1.10 million by 8.67 percent. This is a 34.32 percent increase over sales of $891.16 thousand the same period last year.

Earnings Beats

Earnings Misses

Applied DNA Sciences Q1 EPS $(0.56) Misses $(0.28) Estimate, Sales $1.20M Beat $1.10M Estimate

ABNB

AENT

AGIO

ALNY

AMAT

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

CMRX

MRNA

TNXP

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

Events

Applied Dna Sciences Announced That It Has Rescheduled Its Investor Update Call To Thursday, February 13, 2025

U.S. stock futures climbed on Wednesday in premarket hours as Wall Street awaits the Federal Reserve&#8217;s final interest rate decision for 2024 and its monetary policy forecasts for 2025.
On Tuesday, the Dow Jones index fell for the <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">ninth session in a row</a> to record its longest losing streak since 1978.
The 10-year and two-year Treasury notes yielded 4.40% and 4.25%, respectively. The Federal Open Market Committee will announce its decision later in the day after a two-day meeting.
It is widely expected to announce another interest rate reduction at the conclusion of their meeting on Wednesday. Expectations of a 25 basis point rate cut rose to 95.4%, from 58.7% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
If the Fed cuts rates, it would be the third consecutive cut, bringing the federal funds rate down from its current level of 4.50% to 4.75%. Following the meeting, Chairman Jerome Powell&#8217;s remarks will be closely scrutinized by market participants.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
Prior to that, GDP revisions on Thursday will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.28%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.49%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.25% to $605.80 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.24% to $537.09, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">Dow Jones Industrial Average </a>extended its losing streak to nine consecutive sessions on Tuesday, its longest downturn since 1978. This negative trend weighed on the broader U.S. stock market.
While Tesla shares rallied after a positive analyst upgrade, Nvidia experienced a slight decline.
On the economic front, U.S. retail sales exceeded expectations in November, suggesting increased consumer spending. However, industrial production contracted, signaling a slowdown in manufacturing activity.
The S&amp;P 500 saw a broad-based decline, with industrials, energy, and financials leading the losses. Consumer discretionary stocks, on the other hand, bucked the trend and closed higher.
At the close of trading, the Dow Jones Industrial Average had fallen by approximately 268 points to 43,449.90. The S&amp;P 500 and Nasdaq Composite also ended the day lower, declining by 0.39% and 0.32%, respectively.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.32%</td>
<td>20,109.06</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.39%</td>
<td>6,050.61</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>43,449.90</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.18%</td>
<td>2,334.08</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The Dow Jones Industrial Average index last saw a nine-day fall for the first time since February 1978, according to FactSet data. However, the index has seen steeper crashes in a single day as compared to the cumulative erosion it has witnessed over these nine days.
Dow Jones has fallen nearly 3.47% to 43,449.90 points over the last nine days since Dec. 4, when it was at 45,014.04 points.
&#8220;Since 1900, I see 267 times it lost more than 3.47% in a single day,&#8221; said Ryan Detrick, chief market strategist at Carson Research.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Dow is down 3.47% the past 9 days (and lower all 9 of them). Since 1900, I see 267 times it lost more than 3.47% in a single day.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1869205905780388184?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to BlackRock, the global economy is undergoing a transformation that could keep shifting the long-term economic trend. They suggest that investors should shift to distinct drivers of risk and return.
&#8220;That creates a wide range of potential outcomes and a need to use scenarios to guide portfolio construction, we think. Government bonds have become a less reliable cushion against risk asset selloffs in this new regime. So investors should consider new diversifiers like gold and bitcoin – not to replace bonds, but to get exposure to distinct drivers of risk and return.&#8221;
&#8220;We see the AI buildout and adoption creating opportunities across sectors,&#8221; BlackRock&#8217;s note added.
&#8220;Overall, with so much uncertainty around tariffs and inflation, bond market volatility is unlikely to fade anytime soon,&#8221; said JPMorgan in their note.
&#8220;The week's economic data releases appeared to be enough for markets to solidify expectations for a rate cut at the upcoming Federal Reserve meeting,&#8221; said T Rowe Price in their weekly note.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released this week that will help investors determine the future course of action.
<ul>
<li>On Wednesday, housing starts, and building permit data for November will be announced at 8:30 a.m., ET.</li>
<li>The FOMC&#8217;s interest rate decision will be announced at 2:00 p.m., ET, and the Fed Chair Jerome Powell&#8217;s press conference will begin at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Parazero Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) was up 71.24% in premarket trading after it regained Nasdaq compliance.</li>
<li>Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 45.37% after the company announced it acquired a 51% controlling stake in Star 26 Capital.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose 17.73% in premarket after it said that it would report interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis, on Dec. 18.</li>
<li>Applied DNA Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 13.04% in pre-market trading after reporting weak quarterly sales.</li>
<li>Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) was up 13.28% after it received a NASA contract doe Goddard Space Flight Center to use its entropy quantum optimization machine to help the space agency&#8217;s imaging.</li>
<li>Investors are awaiting earnings results from General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>), Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>, )) and Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.03% to hover around $70.08 per barrel.
The gold spot index rose by 0.08% to $2,664.21 per ounce. The dollar index was up 0.04% to 106.997 level.
Asian markets were mixed on Wednesday, as Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and South Korea&#8217;s Kospi index advanced. Whereas, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index declined. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42548385/fund-managers-increase-allocation-to-banking-and-insurance-stocks-in-december-here-are-the-best-performing-financial-stocks-in-2024">Fund Managers Increase Allocation To Banking And Insurance Stocks In December: Here Are The Best Performing Financial Stocks In 2024</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Futures

Previews

Economics

Federal Reserve

CRVS

NUKK

PRZO

QUBT

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose sharply in today's pre-market trading after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to<a href="https://www.benzinga.com/quote/CRVS"> severe atopic dermatitis</a>.
Corvus Pharmaceuticals shares jumped 22.5% to $9.06 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) gained 88.8% to $2.89 in pre-market trading after gaining 5% on Tuesday. ParaZero Technologies regained Nasdaq compliance.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) climbed 68.4% to $2.19 in pre-market trading after declining over 6% on Tuesday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company announced it has acquired a 51% controlling stake in Star 26 Capital.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) gained 46% to $0.3278 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) rose 33% to $0.4417 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 30.1% to $4.28 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 27.7% to $0.0780 in pre-market trading after jumping 20% on Tuesday.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) gained 26% to $1.55 in pre-market trading after jumping over 26% on Tuesday.</li>
<li>CommScope Holding Company, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 9.1% to $6.12 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares tumbled 29.9% to $0.30 in pre-market trading after jumping 56% on Tuesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) declined 24% to $0.38 in pre-market trading after jumping 87% on Tuesday.</li>
<li>KWESST Micro Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 15.5% to $0.71 in pre-market trading after surging over 15% on Tuesday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 14.7% to $0.1962 in pre-market trading after reporting weak quarterly sales.</li>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) dipped 13.8% to $5.00 in pre-market trading following a 4% decline in the previous session.</li>
<li>FS Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) fell 13.4% to $39.01 in pre-market trading.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 12.5% to $7.90 in today's pre-market trading after jumping 182% on Tuesday.</li>
<li>SHL Telemedicine Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) fell 10% to $3.15 in pre-market trading following a 20% surge on Tuesday.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) fell 9.6% to $32.00 in pre-market trading.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares dipped 8.6% to $36.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>

AUID

CERO

COMM

EFSH

FSBW

NIVF

PRTG

RZLV

SHLT

SSBK

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) to report quarterly earnings at $1.22 per share on revenue of $5.14 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. General Mills shares fell 0.3% to $65.75 in after-hours trading.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) posted better-than-expected results for its second quarter on Tuesday. Worthington shares jumped 14.3% to $43.66 in the after-hours trading session.</li>
<li>Analysts expect Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) to post quarterly earnings at $1.88 per share on revenue of $6.61 billion before the opening bell. Jabil shares gained 0.2% to $134.20 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) reported worse-than-expected fourth-quarter sales results and announced plans for a strategic restructuring of operations including divestiture of certain business segments. Applied DNA Sciences shares dipped 9.6% to $0.2079 in the after-hours trading session.</li>
<li>Analysts expect Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) to post quarterly earnings at $1.76 per share on revenue of $8.72 billion. The company will release earnings after the closing bell. Micron shares gained 0.8% to $109.48 in the after-hours trading session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>
Photo courtesy: Micron

General Mills, Micron Technology And 3 Stocks To Watch Heading Into Wednesday

Applied DNA Sciences shares are trading lower after the company reported worse-than-expected Q4 sales results and announced plans for a strategic restructuring of operations including divestiture of certain business segments.

James A. Hayward remains Chairman of the Board of Directors and Chief Executive Officer.

Management

Applied DNA Reveals Immediate Promotion Of COO Judith Murrah To President; James Hayward Remains Chairman Of Board And CEO

Applied DNA Plans Strategic Restructuring Of Its Business Operations; Seeks Divestiture Of CertainT Platform For Supply Chain Traceability And Authentication

Press Releases

Applied DNA Reschedules Investor Update Call in Observance of the  National Day of Mourning in Recognition of the Passing of  Former President Jimmy Carter

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Applied DNA Reminds Shareholders to Vote Ahead of  Special Meeting on February 14

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Applied DNA Reports First Quarter Fiscal 2025  Financial Results and Highlights Operational Progress

Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A  Laboratory-Developed Test

Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Comments

Applied DNA Sciences

매도 수량

Applied DNA Sciences (NASDAQ:APDN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌